Volume 31, No 1, Jan 2021

ISSN: 1001-0602 
EISSN: 1748-7838 2018 
impact factor 17.848* 
(Clarivate Analytics, 2019)

Volume 31 Issue 1, January 2021: 1-2

RESEARCH HIGHLIGHTS

SARS-CoV-2-induced lung pathology: AHR as a candidate therapeutic target

Federico Giovannoni¹ , Francisco J. Quintana^2,*

¹Ann Romney Center for Neurologic Diseases, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115, USA
²Broad Institute of MIT and Harvard, Cambridge, MA, USA
Correspondence: Francisco J. Quintana(fquintana@rics.bwh.harvard.edu)

The aryl hydrocarbon receptor (AHR) is activated by multiple viruses to evade the host immune response, a strategy exploited in pre-clinical models to limit the replication of Zika and Influenza A. In a recent study, Liu et al. report that AHR drives the hypersecretion of lung mucins after SARS-CoV-2 infection, suggesting a role for AHR in respiratory failure and highlighting its potential therapeutic value.

https://doi.org/10.1038/s41422-020-00447-9

FULL TEXT | PDF

Browse 1017